Literature DB >> 3144552

Effect of method, medium, pH and inoculum on the in-vitro antibacterial activities of fleroxacin and norfloxacin.

P Hohl1, A M Felber.   

Abstract

The comparative in-vitro activities of fleroxacin and norfloxacin were determined by standard agar dilution and broth micro-dilution methods in four different culture media, varying the pH of the medium (pH 5 to pH 8) and the inoculum size. Four inoculum densities equivalent to approximately 10(3), 10(4), 10(5) and 10(6) colony forming units per well or spot were prepared for each of five reference test strains (Escherichia coli ATCC 25922, E. coli ATCC 35218, Staphylococcus aureus ATCC 25923, S. aureus ATCC 29213 and Pseudomonas aeruginosa ATCC 27853). The antibacterial activity of fleroxacin was similar overall to that of norfloxacin and rather uniform. The influence of the test conditions was moderate. However, the activity of both quinolones was uniformly lower at pH 5 in urine and against a high inoculum of 10(6) cfu/spot or well of S. aureus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3144552     DOI: 10.1093/jac/22.supplement_d.71

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  In vitro simulation of in vivo conditions: physical state of the culture medium.

Authors:  V Lorian
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

2.  Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800-mg oral dose.

Authors:  H Hofbauer; K G Naber; M Kinzig-Schippers; F Sörgel; C Rustige-Wiedemann; B Wiedemann; A Reiz; M Kresken
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

3.  Revision of quality control limits for broth microdilution tests of fleroxacin and gentamicin with Pseudomonas aeruginosa ATCC 27853.

Authors:  A L Barry; S D Allen; P C Fuchs; J H Jorgensen; M A Pfaller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-12       Impact factor: 3.267

4.  Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis.

Authors:  J C Akaniro; C E Vidaurre; H R Stutman; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

Review 5.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

Review 6.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

7.  Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers.

Authors:  K G Naber; U Theuretzbacher; M Kinzig; O Savov; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

Review 8.  Quinolone antibacterials. An update of their pharmacology and therapeutic use.

Authors:  N von Rosenstiel; D Adam
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.